These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38334012)

  • 1. Effect of amlodipine on the circulating renin-angiotensin-aldosterone system in healthy cats.
    Garcia Marrero TM; Ward JL; Tropf MA; Bourgois-Mochel A; Guillot E; Domenig O; Yuan L; Kundu D; Mochel JP
    J Vet Intern Med; 2024; 38(2):913-921. PubMed ID: 38334012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy.
    Ward JL; Guillot E; Domenig O; Ware WA; Yuan L; Mochel JP
    J Vet Intern Med; 2022 May; 36(3):897-909. PubMed ID: 35285549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.
    Jepson RE; Syme HM; Elliott J
    J Vet Intern Med; 2014; 28(1):144-53. PubMed ID: 24428319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Renin-Angiotensin-Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine.
    Adin D; Atkins C; Domenig O; Glahn C; DeFrancesco T; Meurs K
    Animals (Basel); 2023 Nov; 13(22):. PubMed ID: 38003097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs.
    Sotillo S; Ward JL; Guillot E; Domenig O; Yuan L; Smith JS; Gabriel V; Iennarella-Servantez CA; Mochel JP
    Sci Rep; 2023 Feb; 13(1):2684. PubMed ID: 36792677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog.
    Atkins CE; Rausch WP; Gardner SY; Defrancesco TC; Keene BW; Levine JF
    J Vet Pharmacol Ther; 2007 Oct; 30(5):394-400. PubMed ID: 17803730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients.
    Nakano N; Ishimitsu T; Takahashi T; Inada H; Okamura A; Ohba S; Matsuoka H
    Int Heart J; 2010 May; 51(3):188-92. PubMed ID: 20558909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Sakatani A; Miyagawa Y; Takemura N
    J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
    Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
    Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
    Steele JL; Henik RA; Stepien RL
    Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs.
    Masters AK; Ward JL; Guillot E; Domenig O; Yuan L; Mochel JP
    PLoS One; 2024; 19(2):e0298030. PubMed ID: 38394253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
    Engeli S; May M; Nussberger J; Danser AHJ; Dole WP; Prescott MF; Dahlke M; Stitah S; Pal P; Boschmann M; Jordan J
    J Am Soc Hypertens; 2017 Aug; 11(8):488-497. PubMed ID: 28666704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism.
    Adin D; Atkins C; Domenig O; DeFrancesco T; Keene B; Tou S; Stern JA; Meurs KM
    J Vet Intern Med; 2020 Mar; 34(2):600-606. PubMed ID: 32112596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.